top of page
Sage Group News
Sage Advises Vesselon on Partnering Its Microbubble Technology for Improving Delivery of Cancer Drug
Sage has been appointed by Vesselon based in Norwalk Connecticut USA. Vesselon uses patents from Columbia University on the use of...
Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy
Sage is representing Mateon Therapeutics, a US-based biopharma company focusing on Vascular Disrupting Agents (VDAs) for orphan oncology...
Opportunity to License or Acquire ES-3000, An Orphan Drug for CML and AML
Escend Therapeutics (www.escendpharma.com) is based in San Diego, CA, and develops small molecule therapeutics for oncology orphan drug...
Sage Group Advises APR on InLicensing and Acquisition of Novel Pharma Products
ABOUT APR Applied Pharma Research s.a. (www.apr.ch; “APR” or the “Company”) is a profitable, well-financed, privately held, Swiss...
Sage Advises Solasia on a Global Partnership for Darinaparsin, a Novel Treatment for Peripheral T Ce
Solasia has engaged The Sage Group to manage a program to establish a global partnership regarding licensing of its Darinaparsin product...
Sage Represents Luzitin in Licensing of its Redaporfin Combination Therapy for Solid Tumours
Sage represents Luzitin (www.luzitin.pt) to develop a strategic alliance for its Redaporfin PDT combination therapy for solid tumours....
Isofol Appoints The Sage Group to Identify Strategic Partnerships for its Novel Modufolin® Chemother
Isofol (www.isofolmedical.com), a clinical stage pharmaceutical company based in Gothenburg, Sweden, announces that following an...
CNSystems Appoints the Sage Group to Identify Strategic Partnerships for its Non Invasive Hemodynami
Graz, Austria, Cambridge UK, and Clinton NJ – January 2015 – CNSystems announces that following an internal strategic assessment, it has...
bottom of page